In Brief: Glaxo Wellcome plc
This article was originally published in The Tan Sheet
Executive Summary
Glaxo Wellcome plc: North American Operations Director Phillip Tracy, who oversaw Burroughs Wellcome's role in the Warner Wellcome OTC joint-venture prior to the Glaxo-Wellcome merger, has resigned, effective June 30. Tracy has headed Glaxo Wellcome's OTC business strategy since the merger. The OTC responsibilities move to James Cochrane as part of his oversight of business and commercial development. Two other executive directors also are resigning -- former Wellcome Group Research, Development and Medical Affairs Director David Barry and Group Marketing Director Keith Merrifield...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning